{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:53:14Z","timestamp":1787961194918,"version":"build-2784847793"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana Per La Ricerca Sul Cancro","doi-asserted-by":"crossref","award":["IG- 2013-ID:14800"],"award-info":[{"award-number":["IG- 2013-ID:14800"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana Per La Ricerca Sul Cancro","doi-asserted-by":"crossref","award":["MFAG 2013-N.14392"],"award-info":[{"award-number":["MFAG 2013-N.14392"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13046-019-1257-1","type":"journal-article","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T14:47:14Z","timestamp":1560437234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures"],"prefix":"10.1186","volume":"38","author":[{"given":"Carminia Maria","family":"Della Corte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusi","family":"Barra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Ciaramella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimondo","family":"Di Liello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Vicidomini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Zappavigna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Luce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Abate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Fiorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Caraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Troiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunato","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriana","family":"Morgillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,13]]},"reference":[{"key":"1257_CR1","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S1010-7940(01)01153-8","volume":"21","author":"O Rena","year":"2002","unstructured":"Rena O, Oliaro A, Cavallo A, Filosso PL, Donati G, Di Marzo P, et al. Stage I non-small cell lung carcinoma: really an early stage? Eur J Cardiothorac Surg. 2002;21:514\u20139.","journal-title":"Eur J Cardiothorac Surg"},{"key":"1257_CR2","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S0140-6736(13)61715-8","volume":"382","author":"R Rosell","year":"2013","unstructured":"Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet. 2013;382:720\u201331.","journal-title":"Lancet"},{"key":"1257_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"1257_CR4","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung Cancer. N Engl J Med. 2015;373:1627\u201339.","journal-title":"N Engl J Med"},{"key":"1257_CR5","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540\u201350.","journal-title":"Lancet."},{"key":"1257_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255\u201365.","journal-title":"Lancet."},{"key":"1257_CR7","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1126\/science.1072682","volume":"298","author":"GL Johnson","year":"2002","unstructured":"Johnson GL, Lapadat R. Mitogen activated protein kinase pathways mediated by ERK, JNK and p38 protein kinases. Science. 2002;298:1911\u20132.","journal-title":"Science."},{"key":"1257_CR8","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","volume":"26","author":"PJ Roberts","year":"2007","unstructured":"Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291\u2013310.","journal-title":"Oncogene."},{"key":"1257_CR9","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1158\/1078-0432.CCR-15-0363","volume":"21","author":"ZA Cooper","year":"2015","unstructured":"Cooper ZA, Reuben A, Austin-Breneman J, Wargo JA. Does it MEK a difference? Understanding immune effects of targeted therapy. Clin Cancer Res. 2015;21:3102\u20134.","journal-title":"Clin Cancer Res"},{"key":"1257_CR10","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","volume":"21","author":"I Liu","year":"2015","unstructured":"Liu I, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and ombination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res. 2015;21:1639\u201351.","journal-title":"Clin Cancer Res"},{"key":"1257_CR11","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1158\/1078-0432.CCR-14-2023","volume":"21","author":"H Kakavand","year":"2015","unstructured":"Kakavand H, Wilmott JS, Menziew AM, Vilain R, Haydu LE, Yearley JH, et al. PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK-inhibitor treated melanoma patients. Clin Cancer Res. 2015;21:3140\u20138.","journal-title":"Clin Cancer Res"},{"key":"1257_CR12","first-page":"435","volume":"7","author":"CC Bancroft","year":"2001","unstructured":"Bancroft CC, Chen Z, Dong G, Sunwoo JB, Yen N, Park C, et al. Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways. Clin Cancer Res. 2001;7:435\u201342.","journal-title":"Clin Cancer Res"},{"key":"1257_CR13","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/ijc.10398","volume":"99","author":"CC Bancroft","year":"2002","unstructured":"Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yen NT, Jackson S, et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer. 2002;99:538\u201348.","journal-title":"Int J Cancer"},{"issue":"9(1)","key":"1257_CR14","doi-asserted-by":"publisher","first-page":"e86537","DOI":"10.1371\/journal.pone.0086537","volume":"22","author":"JP Tsai","year":"2014","unstructured":"Tsai JP, Hsiao PC, Yang SF, Hsieh SC, Bau DT, Ling CL, et al. Licochalcone a suppresses migration and invasion of human hepatocellular carcinoma cells through downregulation of MKK4\/JNK via NF-kappaB mediated urokinase plasminogen activator expression. PLoS One. 2014;22(9(1)):e86537.","journal-title":"PLoS One"},{"key":"1257_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nmeth1015","volume":"4","author":"GY Lee","year":"2007","unstructured":"Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods. 2007;4:359\u201365.","journal-title":"Nat Methods"},{"key":"1257_CR16","first-page":"14","volume":"14","author":"YS DeRose","year":"2013","unstructured":"DeRose YS, Gligorich KM, Wang G, Georgelas A, Bowman P, Courdy SJ, et al. Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine. Curr Protoc Pharmacol. 2013;14:14\u201323.","journal-title":"Curr Protoc Pharmacol"},{"key":"1257_CR17","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/bjc.2011.244","volume":"105","author":"F Morgillo","year":"2011","unstructured":"Morgillo F, Cascone T, D'Aiuto E, Martinelli E, Troiani T, Saintigny P, et al. Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors. Br J Cancer. 2011;105:382\u201392.","journal-title":"Br J Cancer"},{"key":"1257_CR18","doi-asserted-by":"publisher","first-page":"13308","DOI":"10.1073\/pnas.1516689112","volume":"112","author":"F Weeber","year":"2015","unstructured":"Weeber F, van de Wetering M, Hoogstraat M, Dijkstra KK, Krijgsman O, Kuilman T, et al. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. Proc Natl Acad Sci U S A. 2015;112:13308\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1257_CR19","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","volume":"161","author":"M van de Wetering","year":"2015","unstructured":"van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161:933\u201345.","journal-title":"Cell."},{"key":"1257_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14262","volume":"8","author":"M Sch\u00fctte","year":"2017","unstructured":"Sch\u00fctte M, Risch T, Abdavi-Azar N, Boehnke K, Schumacher D, Keil M, et al. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat Commun. 2017;8:14262.","journal-title":"Nat Commun"},{"key":"1257_CR21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","volume":"76","author":"KJ Lastwika","year":"2016","unstructured":"Lastwika KJ, Wilson W 3rd, Li QK, Norris J, Xu H, Ghazarian SR, et al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung Cancer. Cancer Res. 2016;76:227\u201338.","journal-title":"Cancer Res"},{"key":"1257_CR22","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00262-017-2005-z","volume":"66","author":"N Chen","year":"2017","unstructured":"Chen N, Fang W, Lin Z, Peng P, Wang J, Zhan J, et al. KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma. Cancer Immunol Immunother. 2017;66:1175\u201387.","journal-title":"Cancer Immunol Immunother"},{"key":"1257_CR23","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, et al. STK11\/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 2018;8:822\u201335.","journal-title":"Cancer Discov"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1257-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-019-1257-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1257-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T23:07:32Z","timestamp":1591916852000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-019-1257-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,13]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1257"],"URL":"https:\/\/doi.org\/10.1186\/s13046-019-1257-1","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,13]]},"assertion":[{"value":"15 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All human samples and biopsies were collected after obtaining a written informed consensus from any patient and healthy donor, in accordance with the Declaration of Helsinki. The use of these samples for research purposes was approved by our local Ethical Committee of Universit\u00e0 della Campania \u201cLuigi Vanvitelli\u201d.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All human samples and biopsies were collected after obtaining a written informed consensus from any patient and healthy donor, in accordance with the Declaration of Helsinki. The consensus form included the use of these samples for research purposes and consent for publication and was approved by our local Ethical Committee of Universit\u00e0 della Campania \u201cLuigi Vanvitelli\u201d.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EM: Advisory boards: Amgen, Bayer, Merck, Roche, Sanofi, Servier.TT: Advisory boards: Amgen, Bayer, Merck, Roche, Sanofi, Servier, Novartis.FC: Advisory Boards: Roche, Amgen, Merck, Pfizer, Sanofi, Bayer, Servier, BMS, Cellgene, Lilly; Institutional Research Grants: Bayer, Roche, Merck, Amgen, AstraZeneca, Ipsen.FM: Advisory Boards: MSD, Lilly; Institutional Research Grants: AstraZeneca.All other authors have no competing interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"253"}}